NVNO net incomeQ3 2026-$4.37M
NVNO net income was -$4.37M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$4.54M a year earlier. For the full fiscal 2025 it was -$19.47M, compared with -$21.82M in fiscal 2024.
enVVeno Medical Corporation (NVNO) financials
For the twelve months ended Sep 30, 2026, enVVeno Medical Corporation reported -$15.55M of net income.
- Net income, TTM
- -$15.55M
- EPS, diluted, TTM
- -$23.45
- Cash
- $2.58M
- Market cap
- $4.7M
FY2017FY2019
FY2017FY2025
FY2017FY2025
NVNO revenue and earnings growth
NVNO EPSQ3 2026-$6.29
NVNO diluted EPS was -$6.29 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.89 a year earlier. For the full fiscal 2025 it was -$33.06, compared with -$44.53 in fiscal 2024.
NVNO free cash flowQ4 2025-$3.44M
NVNO free cash flow was -$3.44M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$5.11M a year earlier. For the full fiscal 2025 it was -$15.57M, compared with -$16.88M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $31.2K | $186.6K | $422.1K |
| Cost of revenue | - | - | - | - | - | - | - | - | $419.7K |
| Gross profit | - | - | - | - | - | - | - | $186.6K | $2.5K |
| Research and development | $9.98M | $12.25M | $13.58M | $9.91M | $5.73M | $4.25M | $2.21M | $1.24M | $649.7K |
| Selling, general and admin | $10.92M | $11.58M | $11.65M | $15.02M | $11.16M | $4.88M | $4.91M | $6.48M | $5.46M |
| Operating income | -$20.90M | -$23.83M | -$25.24M | -$24.93M | -$16.89M | -$9.14M | -$7.68M | -$7.85M | -$6.10M |
| Pre-tax income | -$19.47M | -$21.82M | - | - | - | - | - | - | - |
| Net income | -$19.47M | -$21.82M | -$23.52M | -$24.67M | -$16.53M | -$9.14M | -$7.63M | -$13.04M | -$7.79M |
| EPS, basic | -$33.06 | -$44.53 | -$66.85 | -$77.00 | -$66.50 | -$263.90 | -$423.50 | -$1531.25 | -$1181.25 |
| EPS, diluted | -$33.06 | -$44.53 | -$66.85 | -$77.00 | -$66.50 | -$263.90 | -$423.50 | -$1531.25 | -$1181.25 |
| Diluted shares | 589,000 | 490,000 | 351,457.143 | 320,857.143 | 247,994.971 | 36,899.114 | 18,011.943 | 10,699.97 | 7,002.085 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.06M | $1.75M | $3.62M | $4.55M | $54.73M | $9.33M | $1.31M | $2.74M | $77.7K |
| Short-term investments | $25.15M | $41.40M | $42.79M | $34.49M | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | $32.0K | $35.2K |
| Current assets | $28.83M | $43.73M | $46.92M | $39.44M | $55.04M | $9.57M | $1.42M | $2.84M | $170.4K |
| Total assets | $29.56M | $44.95M | $48.63M | $41.66M | $57.70M | $10.54M | $3.43M | $3.56M | $2.21M |
| Current liabilities | $2.12M | $2.10M | $1.37M | $1.53M | $1.58M | $3.19M | $1.88M | $1.52M | - |
| Total debt | - | - | - | - | - | - | - | - | $275.0K |
| Total liabilities | $2.43M | $2.79M | $2.44M | $2.93M | $3.29M | $3.44M | $2.44M | $1.52M | $8.17M |
| Shareholders' equity | $27.13M | $42.16M | $46.20M | $38.73M | $54.40M | $7.10M | $989.9K | $2.04M | -$11.13M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.57M | -$16.84M | -$18.86M | -$15.62M | -$11.85M | -$7.68M | -$5.90M | -$6.36M | -$4.20M |
| Capital expenditures | $5.0K | $37.0K | $33.0K | $115.0K | $368.0K | $180.3K | $363.9K | $12.4K | $10.9K |
| Free cash flow | -$15.57M | -$16.88M | -$18.89M | -$15.73M | -$12.22M | -$7.86M | -$6.26M | -$6.37M | -$4.21M |
| Investing cash flow | $15.86M | $1.33M | -$7.87M | -$34.55M | -$368.0K | -$180.3K | -$363.9K | -$12.4K | $165.3K |
| Financing cash flow | $1.02M | $13.64M | $25.79M | - | $57.61M | $15.07M | $5.64M | $9.03M | $4.06M |
| Stock-based compensation | $3.42M | $4.14M | $5.20M | $8.99M | $6.00M | $881.2K | $942.0K | $1.92M | $878.4K |
| Depreciation and amortization | $136.0K | $189.0K | $220.0K | $212.0K | $149.0K | $97.5K | $123.7K | $133.4K | $139.2K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | -83.3% | -55.8% | - |
| Gross margin | - | - | - | - | - | - | - | 100.0% | 0.6% |
| Operating margin | - | - | - | - | - | - | -24566.5% | -4210.5% | -1445.9% |
| Net margin | - | - | - | - | - | - | -24406.7% | -6991.5% | -1845.8% |
| Free cash flow margin | - | - | - | - | - | - | -20037.4% | -3413.7% | -998.1% |
| Return on equity | -71.8% | -51.8% | -50.9% | -63.7% | -30.4% | -128.7% | -770.3% | -640.5% | - |
| Return on assets | -65.9% | -48.5% | -48.4% | -59.2% | -28.6% | -86.7% | -222.0% | -366.4% | -351.8% |
| Current ratio | 13.58 | 20.88 | 34.23 | 25.78 | 34.84 | 3.00 | 0.76 | 1.86 | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.88M | $2.08M | $2.11M | $1.95M | $2.58M | $2.89M | $2.56M | $3.51M | $2.86M | $2.83M | $3.05M | $2.98M |
| Selling, general and admin | $1.66M | $1.72M | $1.95M | $2.06M | $2.30M | $4.16M | $2.40M | $3.19M | $3.31M | $2.63M | $2.45M | $3.30M |
| Operating income | -$4.53M | -$3.80M | -$4.06M | -$4.01M | -$4.88M | -$7.05M | -$4.95M | -$6.70M | -$6.17M | -$5.45M | -$5.50M | -$6.28M |
| Net income | -$4.37M | -$3.60M | -$3.85M | -$3.74M | -$4.54M | -$6.69M | -$4.50M | -$6.23M | -$5.64M | -$4.96M | -$4.99M | -$5.65M |
| EPS, basic | -$6.29 | -$5.37 | -$5.89 | -$5.90 | -$7.89 | -$11.52 | -$7.75 | -$10.58 | -$12.25 | -$10.85 | -$10.85 | -$10.85 |
| EPS, diluted | -$6.29 | -$5.37 | -$5.89 | -$5.90 | -$7.89 | -$11.52 | -$7.75 | -$10.58 | -$12.25 | -$10.85 | -$10.85 | -$10.85 |
| Diluted shares | 694,000 | 671,000 | 654,000 | - | 575,000 | 581,000 | 581,000 | - | 459,057.143 | 459,057.143 | 458,771.429 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.58M | $2.84M | $2.60M | $3.06M | $1.54M | $2.04M | $2.94M | $1.75M | $17.91M | $2.38M | $2.31M | $3.62M |
| Short-term investments | $15.89M | $18.64M | $22.33M | $25.15M | $29.41M | $33.10M | $36.00M | $41.40M | $30.46M | $36.69M | $40.63M | $42.79M |
| Current assets | $19.02M | $22.08M | $25.49M | $28.83M | $31.50M | $35.60M | $39.48M | $43.73M | $49.05M | $39.54M | $43.25M | $46.92M |
| Total assets | $19.49M | $22.66M | $26.10M | $29.56M | $32.35M | $36.58M | $40.58M | $44.95M | $50.39M | $40.99M | $44.83M | $48.63M |
| Current liabilities | $2.59M | $1.89M | $2.14M | $2.12M | $2.40M | $3.02M | $1.66M | $2.10M | $2.23M | $1.70M | $1.49M | $1.37M |
| Total liabilities | $2.59M | $1.99M | $2.35M | $2.43M | $2.90M | $3.52M | $2.27M | $2.79M | $3.02M | $2.58M | $2.46M | $2.44M |
| Shareholders' equity | $16.90M | $20.67M | $23.75M | $27.13M | $29.45M | $33.06M | $38.31M | $42.16M | $47.37M | $38.42M | $42.37M | $46.20M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.18M | -$3.55M | -$3.24M | -$3.44M | -$4.39M | -$3.71M | -$4.02M | -$5.11M | -$4.28M | -$3.91M | -$3.55M | -$4.97M |
| Capital expenditures | - | - | - | $0 | $0 | - | - | $4.0K | $9.0K | $14.0K | $10.0K | $4.0K |
| Free cash flow | - | - | - | -$3.44M | -$4.39M | - | - | -$5.11M | -$4.29M | -$3.92M | -$3.56M | -$4.98M |
| Investing cash flow | $2.73M | $3.67M | $2.77M | $4.18M | $3.65M | $2.82M | $5.20M | -$11.06M | $6.22M | $3.97M | $2.20M | -$22.14M |
| Financing cash flow | $187.0K | - | - | $782.0K | - | - | - | $0 | $13.59M | $0 | $46.0K | - |
| Stock-based compensation | $410.0K | $397.0K | $467.0K | $637.0K | $688.0K | $1.44M | $651.0K | $1.02M | $1.00M | $1.00M | $1.11M | $1.14M |
| Depreciation and amortization | - | - | $31.0K | $31.0K | $31.0K | $34.0K | $40.0K | $40.0K | $43.0K | $51.0K | $55.0K | $55.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 7.35 | 11.70 | 11.89 | 13.58 | 13.12 | 11.81 | 23.77 | 20.88 | 22.01 | 23.33 | 29.08 | 34.23 |
Source: XBRL data enVVeno Medical Corporation files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Mar 31, 2021; 1-for-35, first reported Mar 26, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NVNO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NVNO | - | - | -$15.55M | - | $4.7M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.05B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $95.67B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $61.96B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $57.71B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $52.13B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.10B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $29.62B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $27.85B |
NVNO FAQ
5 questionsIs NVNO profitable?
No. enVVeno Medical Corporation reported a net loss of $15.55M for the twelve months ended Sep 30, 2026.How much cash and debt does NVNO have?
enVVeno Medical Corporation reported $2.58M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is NVNO earnings per share?
Diluted earnings per share were -$23.45 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did NVNO last report financial results?
The latest statements here come from enVVeno Medical Corporation's 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.Where does this NVNO financial data come from?
Quantisnow builds these statements from the structured XBRL data enVVeno Medical Corporation files with the SEC. It is provided for information only and is not investment advice.